Nuformix and VistaGen Announce CNS Agreement

  • Date 27 May 2020

Nuformix plc (LSE:NFX) (“Nuformix” or “the Company”), the pharmaceutical development company focused on unlocking the therapeutic potential and value of known drugs and VistaGen Therapeutics (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system “CNS” diseases and disorders with high unmet need, today announced their agreement to develop novel cocrystal-based formulations of VistaGen’s CNS product candidates.

Read more

Join an ambitious, supportive community of world-class scientists, engineers and entrepreneurs

Read more